Sd Lane, Ce Green, Jl Steinberg, L Ma, Jm Schmitz, N Rathnayaka, Sd Bandak, S Ferre, Fg Moeller
{"title":"新型腺苷A(2A)受体拮抗剂SYN115对可卡因依赖个体的心血管和主观影响。","authors":"Sd Lane, Ce Green, Jl Steinberg, L Ma, Jm Schmitz, N Rathnayaka, Sd Bandak, S Ferre, Fg Moeller","doi":"10.4172/2155-6105.S1-009","DOIUrl":null,"url":null,"abstract":"<p><p>A(2A) receptor antagonists have been proposed as therapeutic tools for dopaminergically-relevant diseases, including Parkinson's disease and substance dependence. The acute subjective and cardiovascular effects of a novel, selective adenosine A(2A) receptor antagonist (SYN115) were examined. Across an 8-hour experimental testing day, 22 non-treatment seeking cocaine-dependent subjects received either placebo capsules (PO) at both the AM and PM dosing times (Plc/Plc, N = 9), or placebo in the AM and 100 mg SYN115 in the PM (Plc/SYN115, N =13). Cardiovascular measures (HR, BP) were obtained across the test day, and subjective effects (ARCI, VAS) were obtained once before and once after the AM and PM doses (four time points total). There were no between-group effects on cardiovascular function, however subjective effects consistent with stimulation were observed on the VAS scales in the SYN115 group. In cocaine-dependent subjects, SYN115 may produce stimulant-like effects through a unique mechanism of action. Due to known monoamine dysfunction related to chronic cocaine use, these effects may be specific to this population relative to healthy control or other patient populations.</p>","PeriodicalId":73583,"journal":{"name":"Journal of addiction research & therapy","volume":"S1 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419540/pdf/nihms391512.pdf","citationCount":"11","resultStr":"{\"title\":\"Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.\",\"authors\":\"Sd Lane, Ce Green, Jl Steinberg, L Ma, Jm Schmitz, N Rathnayaka, Sd Bandak, S Ferre, Fg Moeller\",\"doi\":\"10.4172/2155-6105.S1-009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A(2A) receptor antagonists have been proposed as therapeutic tools for dopaminergically-relevant diseases, including Parkinson's disease and substance dependence. The acute subjective and cardiovascular effects of a novel, selective adenosine A(2A) receptor antagonist (SYN115) were examined. Across an 8-hour experimental testing day, 22 non-treatment seeking cocaine-dependent subjects received either placebo capsules (PO) at both the AM and PM dosing times (Plc/Plc, N = 9), or placebo in the AM and 100 mg SYN115 in the PM (Plc/SYN115, N =13). Cardiovascular measures (HR, BP) were obtained across the test day, and subjective effects (ARCI, VAS) were obtained once before and once after the AM and PM doses (four time points total). There were no between-group effects on cardiovascular function, however subjective effects consistent with stimulation were observed on the VAS scales in the SYN115 group. In cocaine-dependent subjects, SYN115 may produce stimulant-like effects through a unique mechanism of action. Due to known monoamine dysfunction related to chronic cocaine use, these effects may be specific to this population relative to healthy control or other patient populations.</p>\",\"PeriodicalId\":73583,\"journal\":{\"name\":\"Journal of addiction research & therapy\",\"volume\":\"S1 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419540/pdf/nihms391512.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of addiction research & therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-6105.S1-009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of addiction research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-6105.S1-009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
摘要
A(2A)受体拮抗剂已被提议作为多巴胺能相关疾病的治疗工具,包括帕金森病和物质依赖。研究了一种新型选择性腺苷a (2A)受体拮抗剂(SYN115)的急性主观效应和心血管效应。在8小时的实验测试日中,22名寻求可卡因依赖的非治疗受试者在上午和下午给药时间分别服用安慰剂胶囊(Plc/Plc, N = 9),或上午服用安慰剂,下午服用100毫克SYN115 (Plc/SYN115, N =13)。在测试当天获得心血管测量(HR, BP),并在AM和PM给药之前和之后分别获得一次主观效应(ARCI, VAS)(共4个时间点)。在心血管功能方面没有组间效应,但在SYN115组的VAS评分上观察到与刺激一致的主观效应。在可卡因依赖的受试者中,SYN115可能通过一种独特的作用机制产生类似兴奋剂的作用。由于已知的与慢性可卡因使用有关的单胺功能障碍,相对于健康对照或其他患者群体,这些影响可能仅针对该人群。
Cardiovascular and Subjective Effects of the Novel Adenosine A(2A) Receptor Antagonist SYN115 in Cocaine Dependent Individuals.
A(2A) receptor antagonists have been proposed as therapeutic tools for dopaminergically-relevant diseases, including Parkinson's disease and substance dependence. The acute subjective and cardiovascular effects of a novel, selective adenosine A(2A) receptor antagonist (SYN115) were examined. Across an 8-hour experimental testing day, 22 non-treatment seeking cocaine-dependent subjects received either placebo capsules (PO) at both the AM and PM dosing times (Plc/Plc, N = 9), or placebo in the AM and 100 mg SYN115 in the PM (Plc/SYN115, N =13). Cardiovascular measures (HR, BP) were obtained across the test day, and subjective effects (ARCI, VAS) were obtained once before and once after the AM and PM doses (four time points total). There were no between-group effects on cardiovascular function, however subjective effects consistent with stimulation were observed on the VAS scales in the SYN115 group. In cocaine-dependent subjects, SYN115 may produce stimulant-like effects through a unique mechanism of action. Due to known monoamine dysfunction related to chronic cocaine use, these effects may be specific to this population relative to healthy control or other patient populations.